Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.63% | -232.64% | 143.50% | 24.62% | -130.49% |
| Total Depreciation and Amortization | 0.00% | 4.35% | -4.17% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.81% | 102.75% | -318.68% | 166.70% | 2,081.05% |
| Change in Net Operating Assets | 34.35% | -54.89% | 155.36% | -163.34% | 558.21% |
| Cash from Operations | -33.54% | 27.45% | 23.68% | -59.09% | 27.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.52% | 156.01% | 12.25% | -- | -- |
| Cash from Investing | -6.52% | 156.01% | 12.25% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.07% | -74.58% | 13,933.33% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -101.77% | 1,607.22% | -24.59% | -9,107.14% |
| Cash from Financing | 100.31% | -101.31% | 1,636.31% | -105.94% | 193,021.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.83% | -91.64% | 145.65% | -190.98% | 432.52% |